How does Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst (NASDAQ: STLNW) compare with companies in other sectors?

STLNW on the NASDAQ trades at a P/E of N/A with a net margin of 0.00% and ROE of 0.00%, which positions it against peers in the Healthcare sector and beyond.

What are STLNW's (NASDAQ) net and operating margins?

On the NASDAQ, STLNW reports a net profit margin of 0.00% and an operating margin of 0.00%.

In what way does STLNW's (NASDAQ) EPS trend reflect its financial momentum?

STLNW's EPS growth on the NASDAQ is 0.00% and its 5-year EPS CAGR is 0.00%, indicating its earnings momentum.

What does STLNW's (NASDAQ) ROE tell investors?

STLNW on the NASDAQ posts an ROE of 0.00%, showing how much profit Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst generates for every $100 of shareholder equity.

How do I know if STLNW (NASDAQ) is overvalued or undervalued?

STLNW on the NASDAQ trades at a P/E of N/A and a PEG of N/A; compared with the P/E benchmark of 31.57, this suggests valuation should be reviewed against sector peers.

Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst Fundamental Analysis (NASDAQ: STLNW)

STLNW●NASDAQ

HealthcareMedical - Care Facilities

$0.06

$0.003(5.69%)

U.S. Market opens in 49h 38m

Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst Fundamental Analysis (NASDAQ: STLNW)

Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst (NASDAQ: STLNW) shows weak financial fundamentals with a PE ratio of N/A, profit margin of N/A, and ROE of N/A. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

No significant strengths identified.

Areas of Concern

No major concerns flagged.

We analyze STLNW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 0.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

0.0/100

We analyze STLNW's fundamental strength across five key dimensions:

Efficiency Score

Weak

STLNW struggles to generate sufficient returns from assets.

ROA > 10%

N/A

Valuation Score

Weak

STLNW trades at a premium to fair value.

PE < 25

N/A

PEG Ratio < 2

N/A

Growth Score

Weak

STLNW faces weak or negative growth trends.

Revenue Growth > 5%

N/A

EPS Growth > 10%

N/A

Financial Health Score

Weak

STLNW carries high financial risk with limited liquidity.

Debt/Equity < 1

N/A

Current Ratio > 1

N/A

Profitability Score

Weak

STLNW struggles to sustain strong margins.

ROE > 15%

N/A

Net Margin ≥ 15%

N/A

Positive Free Cash Flow

N/A

Key Financial Metrics

Is STLNW Expensive or Cheap?

No data available.

How Well Does STLNW Make Money?

No data available.

Following the Money - Real Cash Generation

No data available.

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

N/A

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

N/A

vs 25 benchmark

P/B Ratio

Price to book value ratio

N/A

vs 25 benchmark

P/S Ratio

Price to sales ratio

N/A

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

N/A

vs 25 benchmark

Current Ratio

Current assets to current liabilities

N/A

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

N/A

vs 25 benchmark

ROA

Return on assets percentage

N/A

vs 25 benchmark

ROCE

Return on capital employed

N/A

vs 25 benchmark

How STLNW Stacks Against Its Sector Peers

Metric	STLNW Value	Sector Average	Performance
P/E Ratio	N/A	31.57	N/A
ROE	N/A	438.00%	N/A
Net Margin	N/A	24098.00%	N/A
Debt/Equity	N/A	0.53	N/A
Current Ratio	N/A	5.57	N/A
ROA	N/A	-195.00% (disorted)	N/A

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst Fundamental Analysis (NASDAQ: STLNW)

Key Strengths

Areas of Concern

Fundamental Health Score

Efficiency Score

Valuation Score

Growth Score

Financial Health Score

Profitability Score

Key Financial Metrics

Is STLNW Expensive or Cheap?

How Well Does STLNW Make Money?

Following the Money - Real Cash Generation

Financial Ratios Analysis

Valuation Ratios

Financial Health

Efficiency Ratios

How STLNW Stacks Against Its Sector Peers

Historical Growth Performance

5-Year Growth Trajectory

Fundamental Analysis FAQ

How does Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst (NASDAQ: STLNW) compare with companies in other sectors?

What are STLNW's (NASDAQ) net and operating margins?

In what way does STLNW's (NASDAQ) EPS trend reflect its financial momentum?

What does STLNW's (NASDAQ) ROE tell investors?

How do I know if STLNW (NASDAQ) is overvalued or undervalued?